iSpecimen Inc. (ISPC) vs XWELL, Inc. (XWEL)
iSpecimen Inc. and XWELL, Inc. are both Diagnostics & Research companies. XWELL, Inc. is the larger, with a market value of $7.6M against $3.1M — 2.4× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −92.1%. XWELL, Inc. has the higher net margin (−117.8% vs −2,449.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, XWELL, Inc. leads on 14 and iSpecimen Inc. on 2.
Valuation
Profitability
| Metric | ISPC | XWEL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (108.26%) | 34.34% | 50.89% |
| Operating margin | (2,020.05%) | (61.31%) | (8.57%) |
| Net margin | (2,449.02%) | (117.83%) | (6.37%) |
| Free cash flow margin | (1,866.61%) | (47.65%) | 0.00% |
| Return on equity | (968.44%) | (557.21%) | (2.92%) |
| Return on assets | (170.09%) | (155.10%) | (6.71%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack